Market Overview

Why Gilead, Galapagos Shares Are Trading Higher

Share:
Why Gilead, Galapagos Shares Are Trading Higher
Related
The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
What's Next For Gilead? (Seeking Alpha)
Related GILD
Fast Money Picks For September 12
The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt
Feds looking into free services from drug makers - WSJ (Seeking Alpha)

GALAPAGOS NV/S ADR (NASDAQ: GLPG) and Gilead Sciences, Inc. (NASDAQ: GILD) were advancing strongly Wednesday following the release of clinical trial data for their pipeline candidate filgotinib.

Galapagos shares were rallying 17.95 percent to $121.18 at the time of publication, while Gilead was up 2.66 percent at $74.15. 

What Happened

Belgian pharma company Galapagos and partner Gilead Sciences announced that their JAK1 inhibitor filgotinib, which is being evaluated in a Phase 3 study dubbed "FINCH 2," achieved significantly higher American College of Rheumatology, or ACR, 20/50/70 percent responses when compared to a placebo in patients with active rheumatoid arthritis and prior inadequate response to biologic agents.

"The primary endpoint was the proportion of patients achieving an ACR20 response at week 12," the companies said.

Filgotinib was tested as a once-daily regimen in 100mg and 200mg doses.

The study also revealed that the pipeline candidate was generally well-tolerated.

Why It's Important

The fact that filgotinib demonstrated significantly improved clinical responses in the difficult-to-treat population bodes well for the results of the FINCH 1 and FINCH 3 trials, which are evaluating the candidate in other patient populations with rheumatoid arthritis.

What's Next

The companies said detailed findings from the FINCH 2 study will be presented at a future scientific conference.

Filgotinib is being evaluated by Galapagos and Gilead for other inflammatory indications such as psoriatic arthritis (Phase 2 EQUATOR Study), ulcerative colitis (Phase 3 SELECTION Study), ankylosing spondylitis (TORTUGA Study) and Crohn's disease (Phase 3 DIVERSITY Study).

Related Links:

The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

New Class of Migraine Drug Creates Four-Way Pharma Development Race

Posted-In: filgotinibBiotech News Movers Trading Ideas Best of Benzinga

 

Related Articles (GILD + GLPG)

View Comments and Join the Discussion!

Copa Holdings' 'Demand Trends Stabilizing,' Buckingham Says In Upgrade

Goldman Downgrades Lam Research, Eyes Downturn In Memory Market